Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
DOXAZOSIN MESYLATE vs HYTRIN
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Selective antagonist of alpha-1 adrenergic receptors on vascular smooth muscle, causing vasodilation and reduced peripheral vascular resistance, leading to decreased blood pressure. Also relaxes smooth muscle in the prostate and bladder neck, improving urinary flow.
Selective alpha-1 adrenergic receptor antagonist; inhibits activation of postsynaptic alpha-1 receptors, resulting in relaxation of smooth muscle in the prostate and bladder neck, improving urinary flow and reducing symptoms of benign prostatic hyperplasia (BPH).
Hypertension,Benign prostatic hyperplasia (BPH),Off-label: Pheochromocytoma (preoperative management), Raynaud's phenomenon, ureteral stones
Benign prostatic hyperplasia (BPH),Hypertension (as monotherapy or in combination with other antihypertensives)
Hypertension: Initial 1 mg PO once daily (morning or bedtime); may increase to 2 mg, 4 mg, 8 mg, or 16 mg once daily as needed. BPH: Initial 1 mg PO once daily, titrate to 2 mg, 4 mg, or 8 mg once daily. Maximum 8 mg/day for BPH, 16 mg/day for hypertension.
Initial: 1 mg orally once daily at bedtime, increase gradually up to 20 mg/day; typical maintenance: 2-10 mg once daily. For BPH: 5-10 mg once daily. For hypertension: 1-5 mg once daily. Maximum: 20 mg/day.
Terminal elimination half-life is approximately 22 hours. This long half-life supports once-daily dosing for hypertension and benign prostatic hyperplasia.
Terminal elimination half-life: 12–13 hours (range 10–15 h); clinical context: steady state achieved in 2–3 days; dose adjustment not required in renal impairment but caution in hepatic impairment.
Extensively metabolized in the liver via O-demethylation and hydroxylation, primarily by CYP3A4.
Extensively metabolized in the liver via demethylation and dehydrogenation; multiple metabolites are formed, some pharmacologically active. CYP450 enzymes involved include CYP3A4 and CYP2D6.
Approximately 63% of the dose is excreted in feces via biliary elimination, and about 9% is excreted unchanged in urine. The remainder is metabolized, with metabolites excreted in urine and feces.
Renal: ~40% as metabolites, <1% unchanged; biliary/fecal: ~60% as metabolites; total clearance 6.4 L/h.
Approximately 98-99% bound to plasma proteins, primarily albumin.
90–94% bound to albumin; free fraction 6–10%.
0.5-1.5 L/kg, indicating extensive distribution into tissues and extravascular spaces.
Vd: 3.9 L/kg (range 3.5–4.3 L/kg); large Vd indicates extensive tissue distribution, high affinity for vascular smooth muscle.
Oral bioavailability is approximately 65% due to first-pass metabolism. Food does not significantly affect absorption.
Oral bioavailability: >90% (first-pass metabolism minimal); food does not affect absorption.
No dose adjustment needed for renal impairment. Doxazosin is minimally renally excreted.
No specific GFR-based dose adjustment required; use with caution in severe renal impairment (Cr Cl <30 m L/min) due to potential accumulation.
Contraindicated in severe hepatic impairment (Child-Pugh C). In mild-moderate impairment (Child-Pugh A or B), use with caution; consider starting at 1 mg once daily and titrate slowly.
Contraindicated in severe hepatic impairment (Child-Pugh class C). For mild to moderate (Child-Pugh A or B), initial dose 1 mg at bedtime, titrate cautiously; monitor for hypotension.
Safety and effectiveness in pediatric patients have not been established. Not recommended for use in children.
Not approved for use in children; safety and efficacy not established.
Use cautiously due to increased risk of orthostatic hypotension, dizziness, and falls. Start at 1 mg once daily, titrate slowly. Monitor blood pressure carefully.
Initiate at 1 mg at bedtime to minimize orthostatic hypotension; titrate slowly. Elderly patients may experience increased sensitivity to hypotensive effects. Monitor blood pressure and renal function.
None
None.
Orthostatic hypotension and syncope, especially with first dose ('first-dose effect'),Risk of intraoperative floppy iris syndrome (IFIS) during cataract surgery,Hepatic impairment may decrease metabolism,Priapism (rare),Drowsiness/somnolence, caution with operating machinery
Orthostatic hypotension and syncope, especially with first dose (first-dose effect); dose titration recommended.,Priapism (rare); advise patient to seek immediate medical attention if erection persists >4 hours.,Intraoperative floppy iris syndrome (IFIS) during cataract surgery in patients on alpha-1 blockers.,Use with caution in patients with renal impairment or hepatic impairment.,May cause dizziness, drowsiness, or blurred vision; caution when driving or operating machinery.
Hypersensitivity to doxazosin or quinazolines,Concomitant use with phosphodiesterase-5 inhibitors (e.g., sildenafil) due to risk of hypotension,Severe hepatic impairment
Hypersensitivity to terazosin or any component of the formulation.,Concomitant use with phosphodiesterase-5 inhibitors (e.g., sildenafil) may increase risk of hypotension (relative contraindication; use with caution).
Avoid grapefruit and grapefruit juice as they may increase drug levels. No other significant food interactions.
No significant food interactions. Avoid grapefruit juice as it may increase drug levels. Take with or without food. Limit alcohol intake as it may enhance orthostatic effects.
FDA Pregnancy Category C. In animal studies, doxazosin showed no teratogenic effects in rats and rabbits at doses up to 20 and 8 mg/kg/day, respectively. There are no adequate and well-controlled studies in pregnant women. Potential fetal risks include possible hypotension and reduced placental perfusion, especially in the second and third trimesters. Use only if potential benefit justifies risk.
Terazosin (HYTRIN) is FDA Pregnancy Category C. No adequate and well-controlled studies in pregnant women. In animal studies, terazosin was not teratogenic in rats or rabbits at doses up to 200 mg/kg/day (rat) and 75 mg/kg/day (rabbit), but delayed fetal ossification was observed. Risk cannot be ruled out; use only if potential benefit justifies potential risk to fetus.
Doxazosin is excreted in human milk. The milk-to-plasma ratio is not reported. Caution is advised; monitor infant for signs of hypotension. Consider alternative therapy in hypertensive mothers during breastfeeding.
It is not known whether terazosin is excreted in human milk. The M/P ratio is unknown. Caution is advised when administered to a nursing woman; consider developmental and health benefits of breastfeeding along with mother's clinical need.
No specific dose adjustments recommended for pregnancy. However, consider increased clearance and volume of distribution, especially in third trimester. Start with lowest effective dose (1 mg/day) and titrate based on blood pressure response. May require more frequent monitoring.
No specific pharmacokinetic data in pregnancy. However, pregnancy may alter volume of distribution and hepatic clearance, potentially affecting drug levels. Dose adjustments may be needed based on clinical response and blood pressure monitoring. Start with lowest effective dose and titrate cautiously.
First-dose syncope can occur; start with 1 mg at bedtime. Titrate slowly based on standing blood pressure. Monitor for orthostatic hypotension, especially in elderly. May cause intraoperative floppy iris syndrome (IFIS) during cataract surgery. Also used for benign prostatic hyperplasia (BPH) and hypertension.
HYTRIN (terazosin) is an alpha-1 adrenergic blocker used for hypertension and benign prostatic hyperplasia (BPH). First-dose syncope can occur; start with 1 mg at bedtime. Titrate slowly to avoid orthostatic hypotension. Monitor blood pressure 2-3 hours after initial dose and after dose increases. May cause intraoperative floppy iris syndrome (IFIS) in cataract surgery; notify ophthalmologist. Use with caution in patients with renal impairment. Can be used alone or with other antihypertensives.
Take the first dose at bedtime to minimize dizziness.,Avoid sudden standing; rise slowly from sitting or lying positions.,May cause drowsiness; do not drive until you know how the medication affects you.,Avoid alcohol, as it can increase dizziness and drowsiness.,Inform your surgeon if you are taking this drug before cataract surgery.,Do not skip doses or discontinue abruptly; consult your doctor.
Take the first dose at bedtime to minimize dizziness or fainting.,Avoid sudden standing or sitting up quickly to prevent orthostatic hypotension.,Report any prolonged erections lasting more than 4 hours immediately.,Avoid driving or hazardous activities until you know how the drug affects you.,Do not stop taking abruptly; consult doctor for gradual dose reduction.,Inform all healthcare providers, especially eye surgeons, that you are taking terazosin.
"Rifampicin is a potent inducer of cytochrome P450 (CYP) 3A4, the primary enzyme responsible for the metabolism of doxazosin. Concurrent use significantly increases doxazosin clearance, reducing its plasma concentration and thereby diminishing its antihypertensive effect. This interaction may lead to loss of blood pressure control, necessitating dose adjustment or alternative therapy."
"Clemastine, a first-generation antihistamine, is primarily metabolized by hepatic cytochrome P450 enzymes, including CYP2D6 and CYP3A4. Doxazosin, an alpha-1 adrenergic receptor antagonist used for hypertension and benign prostatic hyperplasia, can inhibit these CYP isoenzymes, potentially leading to reduced clemastine clearance and elevated plasma concentrations. This may increase the risk of clemastine-related adverse effects such as sedation, anticholinergic toxicity (e.g., dry mouth, urinary retention), and paradoxical CNS stimulation, especially in elderly or renally impaired patients."
"Doxazosin, an alpha-1 adrenergic receptor antagonist, blocks vasoconstriction mediated by catecholamines, thereby opposing the vasopressor effects of ritodrine, a beta-2 adrenergic agonist that also possesses alpha-adrenergic activity. This pharmacodynamic antagonism can reduce the efficacy of ritodrine in achieving uterine relaxation and may lead to inadequate tocolysis or increased risk of maternal hypotension. Clinically, the combination may result in diminished tocolytic response and potential cardiovascular instability."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about DOXAZOSIN MESYLATE vs HYTRIN, answered by our medical review team.
DOXAZOSIN MESYLATE is a Alpha-1 Blocker that works by Selective antagonist of alpha-1 adrenergic receptors on vascular smooth muscle, causing vasodilation and reduced peripheral vascular resistance, leading to decreased blood pressure. Also relaxes smooth muscle in the prostate and bladder neck, improving urinary flow.. HYTRIN is a Alpha-1 Blocker that works by Selective alpha-1 adrenergic receptor antagonist; inhibits activation of postsynaptic alpha-1 receptors, resulting in relaxation of smooth muscle in the prostate and bladder neck, improving urinary flow and reducing symptoms of benign prostatic hyperplasia (BPH).. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between DOXAZOSIN MESYLATE and HYTRIN depend on the specific clinical indication. These are both Alpha-1 Blocker agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of DOXAZOSIN MESYLATE is: Hypertension: Initial 1 mg PO once daily (morning or bedtime); may increase to 2 mg, 4 mg, 8 mg, or 16 mg once daily as needed. BPH: Initial 1 mg PO once daily, titrate to 2 mg, 4 mg, or 8 mg once daily. Maximum 8 mg/day for BPH, 16 mg/day for hypertension.. The standard adult dose of HYTRIN is: Initial: 1 mg orally once daily at bedtime, increase gradually up to 20 mg/day; typical maintenance: 2-10 mg once daily. For BPH: 5-10 mg once daily. For hypertension: 1-5 mg once daily. Maximum: 20 mg/day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between DOXAZOSIN MESYLATE and HYTRIN in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. DOXAZOSIN MESYLATE is classified as Category A/B. FDA Pregnancy Category C. In animal studies, doxazosin showed no teratogenic effects in rats and rabbits at doses up to 20 and 8 mg/kg/day, respectively. There are no adequate and . HYTRIN is classified as Category C. Terazosin (HYTRIN) is FDA Pregnancy Category C. No adequate and well-controlled studies in pregnant women. In animal studies, terazosin was not teratogenic in rats or rabbits at do. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.